Vancomycin-induced red man syndrome in pediatric oncology: Still an issue?

International Journal of Clinical Pharmacy

Volumn 34, Issue 1, 2012, Pages 13-16

  Bauters, Tiene ^a   Claus, Barbara ^a   Schelstraete, Petra ^a   Robays, Hugo ^a   Benoit, Yves ^a   Dhooge, Catharina ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Clinical pharmacy; Pediatric oncology; Red man syndrome; Vancomycin

Indexed keywords

AMIKACIN; DIMETINDENE; PENICILLIN G; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BURNING SENSATION; CASE REPORT; CHILD; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG WITHDRAWAL; HUMAN; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; RED MAN SYNDROME; SEPSIS; SKIN MANIFESTATION; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; ERYTHEMA; INTRAVENOUS DRUG ADMINISTRATION; SYNDROME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; DRUG ERUPTIONS; ERYTHEMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PRURITUS; SYNDROME; VANCOMYCIN;

EID: 84860811909     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9593-z     Document Type: Article

References (19)

1. Levy M, Koren G, Dupuis L, Read SE. Vancomycin-induced red man syndrome. Pediatrics. 1990;86(4):572-80.
2. Polk RE. Red man syndrome. Ann Pharmacother. 1998;32(7-8): 840.
3. Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119-20.
4. Doherty M. Algorithms for assessing the probability of an adverse drug reaction. Respiratory Medicine CME 2. 2009;63-7.
5. Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother. 1997;39(3):371-81.
6. Levy JH, Marty AT. Vancomycin and adverse drug reactions. Crit Care Med. 1993;21(8):1107-8.
7. UpToDate. Inc. Waltham, Massachussets, USA. 2011. http://www.utdol.com. Accessed on July 2011.
8. Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29(4):351-7.
9. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, et al. The study group. continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 2001;45(9):2460-7.
10. Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm. 1997;54:181-4.
11. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2006. URL: http://cp.gsm.com. Updated February 2006.
12. Summary of Product Characteristics Vancocin. 2011. Available from http://www.fagg.be/. Accessed on 13 July 2011.
13. Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis. 1988;157(3):502-7.
14. Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and ''red man syndrome'': comparison of 1-and 2-hour infusions. Antimicrob Agents Chemother. 1990;34(4): 550-4.
15. Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Oral antihis-tamines reduce the side effects from rapid vancomycin infusion. Anesth Analg. 1998;87(3):681-5.
16. Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin-and teicoplanin-induced histamine release and ''red man syndrome''. Antimicrob Agents Chemother. 1990;34(5):765-9.
17. Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother. 2000;12(S) 5:21-5.
18. Wazny LD, Daghigh B. Desensitization protocols for vancomy-cin hypersensitivity. Ann Pharmacother. 2001;35(11):1458-64.
19. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334-6.